P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.
暂无分享,去创建一个
D. Hazuda | Percy Luu | J. Tomassini | Y. Zhu | J. Flygare | D. Price | J. Peng | J. Flygare | C. Blau | H. Mancebo | Junmin Peng | Yuerong Zhu | G. Lee | O. Flores | P. Luu | Gary Lee | Carol Blau
[1] M. Mathews,et al. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. , 1997, Genes & development.
[2] R. Gaynor,et al. Purification of a Tat‐associated kinase reveals a TFIIH complex that modulates HIV‐1 transcription , 1997, The EMBO journal.
[3] Rage,et al. RNase Protection Assay , 1996, Methods.
[4] R. Roeder,et al. Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain , 1996, Nature.
[5] D. Price,et al. Control of RNA Polymerase II Elongation Potential by a Novel Carboxyl-terminal Domain Kinase* , 1996, The Journal of Biological Chemistry.
[6] P. Sharp,et al. Tat-SF1: Cofactor for Stimulation of Transcriptional Elongation by HIV-1 Tat , 1996, Science.
[7] L. Townsend,et al. Synthesis and antiviral evaluation of certain disubstituted benzimidazole ribonucleosides. , 1996, Journal of medicinal chemistry.
[8] M. Dahmus. Reversible Phosphorylation of the C-terminal Domain of RNA Polymerase II* , 1996, The Journal of Biological Chemistry.
[9] D. Bentley,et al. TFIIH functions in regulating transcriptional elongation by RNA polymerase II in Xenopus oocytes , 1996, Molecular and cellular biology.
[10] A. Rice,et al. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function , 1996, Journal of virology.
[11] J. Greenblatt,et al. Three functional classes of transcriptional activation domain , 1996, Molecular and cellular biology.
[12] P. Ghazal,et al. Inhibition of the association of RNA polymerase II with the preinitiation complex by a viral transcriptional repressor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[13] D. Young,et al. Keto/enol epoxy steroids as HIV-1 Tat inhibitors: structure-activity relationships and pharmacophore localization. , 1995, Journal of medicinal chemistry.
[14] A. Rice,et al. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor , 1995, Journal of virology.
[15] M. Groudine,et al. Promoter-proximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation. , 1995, Genes & development.
[16] P. Sharp,et al. Novel mechanism and factor for regulation by HIV‐1 Tat. , 1995, The EMBO journal.
[17] D. Bentley,et al. Transcriptional elongation by RNA polymerase II is stimulated by transactivators , 1994, Cell.
[18] R. Tjian,et al. Transcription factors IIE and IIH and ATP hydrolysis direct promoter clearance by RNA polymerase II , 1994, Cell.
[19] A. Rice,et al. Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. , 1993, Virology.
[20] C. F. Kostrub,et al. RAP30/74 (transcription factor IIF) is required for promoter escape by RNA polymerase II. , 1993, The Journal of biological chemistry.
[21] D. Trono,et al. The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent , 1993, Journal of virology.
[22] J. T. Kadonaga,et al. In vivo and in vitro analysis of transcriptional activation mediated by the human cytomegalovirus major immediate-early proteins , 1993, Molecular and cellular biology.
[23] D. Richman,et al. Discovery and characterization of an HIV-1 Tat antagonist. , 1992, Biochemical Society transactions.
[24] D. Reinberg,et al. Factors involved in specific transcription by mammalian RNA polymerase II. Identification and characterization of factor IIH. , 1992, The Journal of biological chemistry.
[25] R. Tjian,et al. Structure and functional properties of human general transcription factor IIE , 1991, Nature.
[26] P. Sharp,et al. HIV‐1 Tat protein promotes formation of more‐processive elongation complexes. , 1991, The EMBO journal.
[27] K. Jones,et al. Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin. , 1991, Genes & Development.
[28] D. Reinberg,et al. The nonphosphorylated form of RNA polymerase II preferentially associates with the preinitiation complex. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[29] D. Reinberg,et al. Cloning of a human gene encoding the general transcription initiation factor IIB , 1991, Nature.
[30] D. Baltimore,et al. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[31] M. Mathews,et al. Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation. , 1990, Genes & development.
[32] I. Sim. The Human Immunodeficiency Virus TAT Protein , 1990 .
[33] Phillip A. Sharp,et al. HIV-1 Tat protein trans-activates transcription in vitro , 1990, Cell.
[34] G. Casey,et al. Human chromosome 12 encodes a species-specific factor which increases human immunodeficiency virus type 1 tat-mediated trans activation in rodent cells , 1990, Journal of virology.
[35] M. Mathews,et al. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation , 1989, Cell.
[36] P. Sharp,et al. 5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription elongation by RNA polymerase II in vitro. , 1989, The Journal of biological chemistry.
[37] D. Reinberg,et al. Factors involved in specific transcription in mammalian RNA polymerase II. Functional analysis of initiation factors IIA and IID and identification of a new factor operating at sequences downstream of the initiation site. , 1987, The Journal of biological chemistry.
[38] R. Weinmann,et al. Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription. , 1986, The Journal of biological chemistry.
[39] R. Weinmann,et al. Inhibitory effect of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole on a protein kinase. , 1984, The Journal of biological chemistry.
[40] G. Molloy,et al. Induction of premature termination of transcription of the mouse β-globin gene by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) , 1981 .
[41] Y. Aloni,et al. 5,6-dichloro-1-beta-ribofuranosylbenzimidazole enhances premature termination of late transcription of simian virus 40 DNA. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[42] I. Tamm,et al. Early termination of heterogeneous nuclear RNA transcripts in mammalian cells: accentuation by 5,6-dichloro 1-beta-D-ribofuranosylbenzimidazole. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[43] J. Darnell,et al. Multiple discrete sites for premature RNA chain termination late in adenovirus-2 infection: enhancement by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[44] V. Byrnes,et al. A system to analyze and identify inhibitors of HIV-1 gene regulation using a defective integrated provirus. , 1996, Methods in enzymology.
[45] B. Peterlin,et al. Control of RNA initiation and elongation at the HIV-1 promoter. , 1994, Annual review of biochemistry.